America’s Food and Drug Administration approved a medication produced by Eli Lilly, a pharmaceutical firm, for weight-loss use. The injectable, called Zepbound, is part of a new generation of obesity drugs, and has the same active ingredient as Mounjaro, which is already approved to treat diabetes. It will compete against Novo Nordisk’s Wegovy, the weight-loss version of Ozempic.
America’s Food and Drug Administration approved a medication...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$32.79 |
Change
0.210(0.64%) |
Mkt cap ! $20.39B | |||
| Open | High | Low | Value | Volume |
| $32.85 | $32.97 | $32.73 | $70.28M | 2.146M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 2339 | $32.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $32.80 | 168 | 1 |
View Market Depth
| Last trade - 11.18am 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$32.79 |
Change
0.210 ( 0.75 %) |
||||
| Open | High | Low | Volume | ||
| $32.85 | $32.96 | $32.74 | 224961 | ||
| Last updated 11.36am 30/04/2024 ? | |||||
| RMD (ASX) Chart |